The latest price target for Akero Therapeutics (NASDAQ:AKRO) was reported by HC Wainwright & Co. on January 16, 2025. The analyst firm set a price target for $50.00 expecting AKRO to rise to within 12 months (a possible 99.84% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Akero Therapeutics (NASDAQ:AKRO) was provided by HC Wainwright & Co., and Akero Therapeutics reiterated their buy rating.

The last upgrade for Akero Therapeutics Inc happened on January 27, 2023 when Morgan Stanley raised their price target to $65. Morgan Stanley previously had an equal-weight for Akero Therapeutics Inc.

There is no last downgrade for Akero Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on January 16, 2025 so you should expect the next rating to be made available sometime around January 16, 2026.

While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a reiterated with a price target of $50.00 to $50.00. The current price Akero Therapeutics (AKRO) is trading at is $25.02, which is out of the analyst’s predicted range.